Intelligent Bio Solutions (NASDAQ: INBS) grants director 5,000 restricted shares

Rhea-AI Filing Summary

Fraser Nicola Marion reported acquisition or exercise transactions in this Form 4 filing.

INTELLIGENT BIO SOLUTIONS INC. director Fraser Nicola Marion received an equity award rather than conducting an open‑market trade. On March 18, 2026, the company granted him 5,000 restricted shares of Common Stock under its 2019 Long Term Incentive Plan, at no cash purchase price.

The restricted shares vest based on time after 12 months and may be forfeited if vesting conditions are not met. Following this grant, Marion holds 5,000 shares of Common Stock directly, with all amounts presented on a post‑reverse‑split basis after the company’s prior reverse stock splits.

Insights

Equity compensation analyst

Routine director equity grant of 5,000 restricted shares.

Fraser Nicola Marion, a director of INTELLIGENT BIO SOLUTIONS INC., was granted 5,000 restricted shares of Common Stock on March 18, 2026 under the 2019 Long Term Incentive Plan. The grant is compensation-related, not an open-market transaction.

The shares vest after 12 months and are subject to forfeiture until vested, so economic benefit depends on continued service and future share value. After this award, Marion holds 5,000 shares directly. As a single, modest-sized grant with standard vesting, it appears routine and does not by itself signal a major change in outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fraser Nicola Marion

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		5,000(2)	A	$0	5,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

	/s/ Nicola Fraser	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INBS director Fraser Nicola Marion report on this Form 4?

Fraser Nicola Marion reported receiving an equity award, not a market trade. On March 18, 2026, Intelligent Bio Solutions Inc. granted him 5,000 restricted shares of Common Stock as compensation under its 2019 Long Term Incentive Plan, with time-based vesting conditions.

How many INBS shares were granted to Fraser Nicola Marion and on what terms?

The company granted Fraser Nicola Marion 5,000 restricted shares of Common Stock. These shares were awarded under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan, carry no purchase price, and are subject to time-based vesting after 12 months and potential forfeiture until vested.

Is the INBS Form 4 transaction a stock purchase or a compensation grant?

The Form 4 reflects a compensation-related grant, not a stock purchase. Intelligent Bio Solutions Inc. awarded Fraser Nicola Marion 5,000 restricted shares of Common Stock as a grant or award, consistent with director equity compensation practices, with vesting requirements rather than an open-market buy order.

What are the vesting conditions for the 5,000 INBS restricted shares granted to Marion?

The 5,000 restricted shares of Intelligent Bio Solutions Inc. Common Stock vest based on time after 12 months. Until they vest, the shares are subject to forfeiture, meaning Marion’s continued service and satisfaction of vesting terms determine whether he keeps the full award.

How many INBS shares does Fraser Nicola Marion hold after this reported transaction?

After this grant, Fraser Nicola Marion holds 5,000 shares of Intelligent Bio Solutions Inc. Common Stock directly. All share amounts in the Form 4 are presented on a post‑reverse‑split basis, reflecting the company’s prior reverse stock splits, including a 1‑for‑10 split in December 2025.

How did prior reverse stock splits affect the INBS share amounts in this Form 4?

A 1‑for‑10 reverse stock split in December 2025, plus earlier reverse splits, reduced the number of INBS shares held and adjusted equity awards proportionally. As a result, all share figures in this Form 4, including the 5,000 restricted shares, are shown on a post‑reverse‑split basis.